Drug Safety Experts assess and ensure the safety of pharmaceutical products throughout their lifecycle, from development to post-market surveillance. They focus on identifying, evaluating, and mitigating the risks associated with drug use, including adverse reactions, drug interactions, and long-term effects. These experts play a key role in monitoring the safety of medications once they reach the market, conducting pharmacovigilance to detect and analyze any potential safety concerns that arise in the general population. Their work is essential in protecting public health by ensuring that the benefits of a drug outweigh its risks. They also provide crucial feedback to pharmaceutical companies, ensuring that any potential risks are addressed before the product is launched. These are collaborate with regulatory agencies, pharmaceutical companies, and healthcare providers to ensure that appropriate risk management strategies are in place. They are responsible for analyzing clinical trial data, conducting risk-benefit assessments, and providing recommendations for label changes, warnings, or even drug withdrawals if necessary. Drug safety experts also play a key role in the development of safer drugs, contributing to the design of clinical trials that minimize risks and maximize patient safety. By utilizing sophisticated monitoring techniques and real-time data, they ensure that drugs remain safe for use across diverse populations and over extended periods.
Title : Medical liver biopsy: Toward a personalized approach
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Mathematical modeling the disc diffusion test: Antibacterial activity of copper-doped SnO2
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Antibody-proteases as translational tools of the next-step generation to be applied for biopharmacy-related and precision medical practice
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Storage stability and solution binding affinity of an fc-fusion mimetic
Hanieh Khalili, University of East London, United Kingdom
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia